The company reported a net loss of $16.3 million, or 13 cents per share, a sharp improvement from the $49 million loss recorded in the same period last year. This performance comfortably beat FactSet analyst consensus, which had forecasted a wider loss of 20 cents per share. Revenue for the quarter reached $166 million, edging past the $165 million reported a year ago and exceeding the $159.7 million anticipated by Wall Street.

International Growth and 2026 Outlook

While the company faced headwinds in its domestic market, growth in international segments provided a necessary cushion. Revenue declined across the Americas but saw gains in the Europe, Middle East, and Africa (EMEA) and Asia-Pacific regions. This shift highlights a diversifying revenue base as the company navigates a complex global biotech landscape.

Looking ahead, 10x Genomics provided a specific outlook for the mid-term. The company projects 2026 full-year revenue to fall between $600 million and $625 million. According to the company’s forecast, this represents flat to 4% growth when adjusted to exclude non-recurring income from patent litigation settlements received in the previous year.

Investors reacted positively to the narrowing losses, pushing the stock to $19.41 in late morning trading on Friday. The recent rally contributes to a broader upward trend for the biotech firm, which has seen its share price appreciate by 60% over the past twelve months.